Publications by authors named "Graham Dark"

Claim this Profile
W
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Andrew R Clamp, Elizabeth C James, Iain A McNeish, Andrew Dean, Jae-Won Kim, Graham Dark

Lancet Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Robert D Morgan, Iain A McNeish, Adrian D Cook, Elizabeth C James, Rosemary Lord, Graham Dark

Lancet Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.
Sarah P Blagden, Adrian D Cook, Christopher Poole, Lesley Howells, Ian A McNeish, Graham Dark

Lancet Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Andrew R Clamp, Elizabeth C James, Iain A McNeish, Andrew Dean, Jae-Weon Kim, Graham Dark

Lancet· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Martin Gore, Allan Hackshaw, William E Brady, Richard T Penson, Richard Zaino, Graham Dark

Gynecol Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of a 2-Week Oncology Placement on Medical Students' Perception of Cancer.
Jonathan Mayes, Simon Davies, Andrew Harris, Emma Wray, Graham G Dark

J Cancer Educ· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients.
Richard Baird, Ian Banks, David Cameron, John Chester, Helena Earl, Graham Dark

Ecancermedicalscience· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.
Ignace B Vergote, Agustin Garcia, John Micha, Charles Pippitt, Johanna Bendell, Graham Dark

J Clin Oncol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
Paul Taylor, Bruno Castagneto, Graham Dark, Maurizio Marangolo, Giorgio V Scagliotti

J Thorac Oncol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of vinflunine in malignant pleural mesothelioma.
Denis C Talbot, Jacques Margery, Gérard Dabouis, Graham Dark, Henry Taylor

J Clin Oncol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
Graham G Dark, A Hilary Calvert, Robert Grimshaw, Christopher Poole, Ken Swenerton

J Clin Oncol· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differentiation and definition of vascular-targeted therapies.
Dietmar W Siemann, Michael C Bibby, Graham G Dark, Adam P Dicker, Ferry A L M Eskens

Clin Cancer Res· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
Giorgio V Scagliotti, Cornelius Kortsik, Graham G Dark, Allan Price, Christian Manegold

Clin Cancer Res· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in mesothelioma.
Graham Dark

Clin Med (Lond)· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis